Revolutionizing Cancer Therapeutics with Innovative BAK Activation
Inspired by discoveries from the lab to the patient’s bedside, we excel in translating scientific knowledge into targeted and precision medicines to eradicate cancer.
BAK Activation for Apoptosis
Developing cancer therapeutics targeting BAK, inducing apoptotic cell death through mitochondrial pore formation.
Small Molecule BAK Activator
First-in-class BAK activator selectively eliminates cancer cells, suppressing tumor growth while sparing normal tissues.
BAK Activator-Linked Antibody Drug Conjugates
Advancing with BAK activator-linked antibody drug conjugates to enhance treatment effectiveness and minimize off-target toxicities.
About Us
Welcome to 7 Primus, pioneers in cancer therapeutics. We’re revolutionizing treatment with our groundbreaking BAK activator—a first-in-class, small molecule that selectively targets and eliminates cancer cells. Our in vivo studies showcase its remarkable ability to suppress tumor growth while minimizing harm to normal tissues.
Building on this success, we’re developing BAK activator-linked antibody drug conjugates. By combining antibody specificity with the anti-tumor potency of 7PB-100, we aim to provide highly effective and precise cancer treatments, minimizing side effects for the benefit of patients. Join us as we redefine the future of cancer care.
